We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) International Revenue in Focus: Trends and Expectations
Read MoreHide Full Article
Have you evaluated the performance of Hologic's (HOLX - Free Report) international operations during the quarter that concluded in June 2024? Considering the extensive worldwide presence of this medical device maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.
In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors now place great importance on grasping the extent of a company's dependence on international markets, as it sheds light on the firm's earnings stability, its skill in leveraging various economic cycles and its broad growth potential.
Participation in global economies acts as a defense against economic difficulties at home and a pathway to more rapidly developing economies. However, it also comes with the complexities of dealing with fluctuating currencies, geopolitical risks and different market dynamics.
While analyzing HOLX's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.
The company's total revenue for the quarter stood at $1.01 billion, increasing 2.7% year over year. Now, let's delve into HOLX's international revenue breakdown to gain insights into the significance of its operations beyond home turf.
Decoding HOLX's International Revenue Trends
During the quarter, Rest of World contributed $53.2 million in revenue, making up 5.3% of the total revenue. When compared to the consensus estimate of $57.32 million, this meant a surprise of -7.19%. Looking back, Rest of World contributed $57 million, or 5.6%, in the previous quarter, and $42.9 million, or 4.4%, in the same quarter of the previous year.
Of the total revenue, $127.9 million came from Europe during the last fiscal quarter, accounting for 12.7%. This represented a surprise of +1.53% as analysts had expected the region to contribute $125.97 million to the total revenue. In comparison, the region contributed $137 million, or 13.5%, and $128.5 million, or 13.1%, to total revenue in the previous and year-ago quarters, respectively.
Asia-Pacific generated $65 million in revenues for the company in the last quarter, constituting 6.4% of the total. This represented a surprise of +0.76% compared to the $64.51 million projected by Wall Street analysts. Comparatively, in the previous quarter, Asia-Pacific accounted for $64.4 million (6.3%), and in the year-ago quarter, it contributed $62.9 million (6.4%) to the total revenue.
Revenue Forecasts for the International Markets
Wall Street analysts expect Hologic to report a total revenue of $984.62 million in the current fiscal quarter, which suggests an increase of 4.2% from the prior-year quarter. Revenue shares from Rest of World, Europe and Asia-Pacific are predicted to be 6.2%, 12.7% and 6.6%, corresponding to amounts of $60.99 million, $124.88 million and $64.72 million, respectively.
For the full year, a total revenue of $4.03 billion is expected for the company, reflecting a decline of 0.1% from the year before. The revenues from Rest of World, Europe and Asia-Pacific are expected to make up 5.7%, 13.2% and 6.4% of this total, corresponding to $228.12 million, $530.65 million and $257.43 million respectively.
Final Thoughts
Relying on global markets for revenues presents both prospects and challenges for Hologic. Therefore, scrutinizing its international revenue trends is key to effectively forecasting the company's future outlook.
In a world where international interdependencies and geopolitical conflicts are ever-increasing, Wall Street analysts closely monitor these trends for companies having international presence to adjust their earnings forecasts. Of course, there are several other factors, including a company's standing within its home borders, that influence analysts' earnings forecasts.
Emphasizing a company's shifting earnings prospects is a key aspect of our approach at Zacks, especially since research has proven its substantial influence on a stock's price in the short run. This correlation is positively aligned, meaning that improved earnings projections tend to boost the stock's price.
The Zacks Rank, our proprietary stock rating mechanism, demonstrates a notable performance history confirmed through external audits. It effectively utilizes the power of earnings estimate revisions to act as a predictor of a stock's price performance in the near term.
The stock has increased by 12.9% over the past month compared to the 2.9% fall of the Zacks S&P 500 composite. Meanwhile, the Zacks Medical sector, which includes Hologic, has increased 3.2% during this time frame. Over the past three months, the company's shares have experienced a gain of 11.3% relative to the S&P 500's 5.9% increase. Throughout this period, the sector overall has witnessed a 5.1% increase.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) International Revenue in Focus: Trends and Expectations
Have you evaluated the performance of Hologic's (HOLX - Free Report) international operations during the quarter that concluded in June 2024? Considering the extensive worldwide presence of this medical device maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.
In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors now place great importance on grasping the extent of a company's dependence on international markets, as it sheds light on the firm's earnings stability, its skill in leveraging various economic cycles and its broad growth potential.
Participation in global economies acts as a defense against economic difficulties at home and a pathway to more rapidly developing economies. However, it also comes with the complexities of dealing with fluctuating currencies, geopolitical risks and different market dynamics.
While analyzing HOLX's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.
The company's total revenue for the quarter stood at $1.01 billion, increasing 2.7% year over year. Now, let's delve into HOLX's international revenue breakdown to gain insights into the significance of its operations beyond home turf.
Decoding HOLX's International Revenue Trends
During the quarter, Rest of World contributed $53.2 million in revenue, making up 5.3% of the total revenue. When compared to the consensus estimate of $57.32 million, this meant a surprise of -7.19%. Looking back, Rest of World contributed $57 million, or 5.6%, in the previous quarter, and $42.9 million, or 4.4%, in the same quarter of the previous year.
Of the total revenue, $127.9 million came from Europe during the last fiscal quarter, accounting for 12.7%. This represented a surprise of +1.53% as analysts had expected the region to contribute $125.97 million to the total revenue. In comparison, the region contributed $137 million, or 13.5%, and $128.5 million, or 13.1%, to total revenue in the previous and year-ago quarters, respectively.
Asia-Pacific generated $65 million in revenues for the company in the last quarter, constituting 6.4% of the total. This represented a surprise of +0.76% compared to the $64.51 million projected by Wall Street analysts. Comparatively, in the previous quarter, Asia-Pacific accounted for $64.4 million (6.3%), and in the year-ago quarter, it contributed $62.9 million (6.4%) to the total revenue.
Revenue Forecasts for the International Markets
Wall Street analysts expect Hologic to report a total revenue of $984.62 million in the current fiscal quarter, which suggests an increase of 4.2% from the prior-year quarter. Revenue shares from Rest of World, Europe and Asia-Pacific are predicted to be 6.2%, 12.7% and 6.6%, corresponding to amounts of $60.99 million, $124.88 million and $64.72 million, respectively.For the full year, a total revenue of $4.03 billion is expected for the company, reflecting a decline of 0.1% from the year before. The revenues from Rest of World, Europe and Asia-Pacific are expected to make up 5.7%, 13.2% and 6.4% of this total, corresponding to $228.12 million, $530.65 million and $257.43 million respectively.
Final Thoughts
Relying on global markets for revenues presents both prospects and challenges for Hologic. Therefore, scrutinizing its international revenue trends is key to effectively forecasting the company's future outlook.In a world where international interdependencies and geopolitical conflicts are ever-increasing, Wall Street analysts closely monitor these trends for companies having international presence to adjust their earnings forecasts. Of course, there are several other factors, including a company's standing within its home borders, that influence analysts' earnings forecasts.
Emphasizing a company's shifting earnings prospects is a key aspect of our approach at Zacks, especially since research has proven its substantial influence on a stock's price in the short run. This correlation is positively aligned, meaning that improved earnings projections tend to boost the stock's price.
The Zacks Rank, our proprietary stock rating mechanism, demonstrates a notable performance history confirmed through external audits. It effectively utilizes the power of earnings estimate revisions to act as a predictor of a stock's price performance in the near term.
Hologic currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Hologic's Recent Stock Market Performance
The stock has increased by 12.9% over the past month compared to the 2.9% fall of the Zacks S&P 500 composite. Meanwhile, the Zacks Medical sector, which includes Hologic, has increased 3.2% during this time frame. Over the past three months, the company's shares have experienced a gain of 11.3% relative to the S&P 500's 5.9% increase. Throughout this period, the sector overall has witnessed a 5.1% increase.